Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2014; 20(1): 118-125
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.118
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.118
Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors
Ting-Ting Li, Jun Wan, Ben-Yan Wu, Department of Geriatric Gastroenterology, Chinese People’s Liberation Army General Hospital, Beijing 100853, China
Feng Qiu, Xiao-Kun Qi, Department of Neurology, Chinese Navy General Hospital, Beijing 100048, China
Zhi Rong Qian, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States
Author contributions: Li TT and Qiu F did problem formulation; Qian ZR performed literature search; Li TT and Qiu F wrote the paper; and Wan J, Qi XK and Wu BY revised the manuscript.
Supported by National Natural Scientific Foundation of China, No. B1070296
Correspondence to: Ben-Yan Wu, Professor, Department of Geriatric Gastroenterology, Chinese People’s Liberation Army General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China. benyanwu@vip.sina.com
Telephone: +86-10-66876265 Fax: +86-10-66876265
Received: August 30, 2013
Revised: October 31, 2013
Accepted: November 18, 2013
Published online: January 7, 2014
Revised: October 31, 2013
Accepted: November 18, 2013
Published online: January 7, 2014
Core Tip
Core tip: Gastric neuroendocrine tumors (GNETs) comprise distinct tumor entities that have been classified on the basis of pathogenesis and histomorphologic characteristics into 4 types that differ in biological behavior and prognosis. To plan the correct management and optimal therapeutic approach in patients with GNETs, it is essential to obtain an adequate clinical evaluation and assessment of the pathological features of the tumor. Development of new gene markers as well as effective drugs is expected for the better diagnosis, prognosis and treatment of GNETs.